United Therapeutics Corporation Financials

Market Capitalization $16.60 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	16.34
Forward PE	13.34
Price to Sales TTM	$6.02
Price to Book MRQ	$2.72
Enterprise to Revenue	4.96
Enterprise to EBITDA	9.69

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	40.31%
Operating Margin	54.51%
Return on Assets TTM	11.89%
Return on Equity TTM	18.81%

Income Statement

Revenue TTM	$2,756,199,936
Revenue per Share TTM	$60.25
Quarterly Revenue Growth	22.90%
Gross Profit TTM	$2,451,399,936
EBITDA	$1,619,600,000
Net Income to Common TTM	$1,110,899,968
Diluted EPS TTM	$22.76
Quarterly Earnings Growth YoY	15.50%

Balance Sheet

Total Cash MRQ	$3,326,500,096
Total Cash per Share MRQ	$74.51
Total Debt MRQ	$
Total Debt to Equity MRQ	6.56
Current Ratio MRQ	4.58
Book Value per Share MRQ	$136.74

Cash Flow

Operating Cash Flow TTM	$1,136,600,064
Levered Free Cash Flow TTM	$710,087,488

UTHR Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	44,644,500
Float Shares	40,925,631
Avg 10 Volume	311,300
Avg 30 Volume	None
Shares Short	1,921,334
Short Ratio	6.47
Short % of Shares	5.67%
% Held by Insiders	1.85%
% Held by Institutions	99.84%

Stock Price Summary

Beta	0.56
Fifty Two Week Low	$208.62
Fifty Two Week High	$417.82
Fifty Two Week Change	41.51%
Day 50 MA	$368.65
Day 200 MA	$328.77

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2009-09-23